The U.S. Food and Drug Administration (FDA) has granted a significant regulatory expansion for ViiV Healthcare’s Tivicay PD (dolutegravir), a dispersible tablet formulation of the potent integrase strand transfer inhibitor (INSTI). This approval marks a pivotal shift in pediatric HIV management, as the drug is now indicated for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, effective from birth. By removing the previous minimum-age requirement and lowering the weight threshold, the FDA has addressed a critical therapeutic vacuum that has historically left the youngest and most vulnerable patients with limited, optimized antiretroviral options.
A Chronology of Clinical Evolution
The journey of dolutegravir from an adult-focused therapy to a neonatal treatment represents a decade of clinical refinement. When the FDA first granted approval for Tivicay in August 2013, it was strictly intended for adults and adolescents aged 12 years or older who weighed at least 40 kg. The drug’s high genetic barrier to resistance and favorable safety profile quickly established it as a backbone of modern HIV therapy.
Following its initial success, ViiV Healthcare pursued a strategy of pediatric de-escalation, aiming to bring the benefits of the drug to younger populations. In 2020, the agency authorized the dispersible tablet formulation (Tivicay PD) for infants as young as four weeks old who weighed at least 3 kg. The most recent regulatory milestone—extending the indication to include newborns weighing as little as 2 kg—is the culmination of years of pharmacokinetic (PK) modeling and rigorous clinical investigation, most notably the NIH-funded IMPAACT 2023 study.
The IMPAACT 2023 Trial: Methodology and Findings
The IMPAACT 2023 study was a multicenter, phase 1 clinical trial designed to tackle the complexities of neonatal drug metabolism. Because newborns possess immature metabolic pathways, determining appropriate dosing—especially for infants with low birth weights—is fraught with physiological challenges.
The study enrolled 48 mother-infant pairs across clinical sites in South Africa, Thailand, and the United States. Researchers administered Tivicay PD to HIV-exposed newborns from birth for up to six weeks, often in conjunction with existing standard-of-care antiretroviral protocols used to prevent mother-to-child transmission. The study design followed these infants for a 16-week period to ensure sustained tolerability and safety.
The data revealed that the pharmacokinetics of dolutegravir in these neonates were comparable to exposures observed in adults, where the drug has proven highly effective at suppressing viral loads. Furthermore, the safety profile identified in the neonates was consistent with that seen in older pediatric and adult cohorts, with no new safety signals emerging. Detailed results from a 15-infant chronic-dosing sub-cohort, presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in 2025, highlighted the feasibility of a 5-mg dosage regimen, which began with every-other-day dosing for the first two weeks, transitioning to daily administration thereafter.
The Global Burden and the Treatment Gap
The necessity for this approval is underscored by sobering global health statistics. UNICEF has consistently reported that without rapid and effective intervention, approximately 50% of infants living with HIV will not survive to see their second birthday. Early initiation of antiretroviral therapy (ART) is the most critical factor in reducing mortality and improving long-term health outcomes for vertically infected infants.
While the United States has made immense strides in perinatal care, with the rate of mother-to-child transmission now reduced to 1% or less, the global picture remains disparate. In the U.S., perinatal HIV infections are relatively infrequent, with fewer than 50 cases reported annually since 2018. However, the FDA’s approval of Tivicay PD provides a gold-standard option for these rare but high-stakes cases, ensuring that clinicians are not forced to rely on older, less tolerable, or less effective medication regimens when treating a newborn in the first hours or days of life.
Official Perspectives and Expert Commentary
Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and the lead investigator for the IMPAACT 2023 study, emphasized the long-standing deficiency in neonatal drug development. "For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," she noted in a statement. Her endorsement underscores the academic and clinical consensus that pediatric labeling must be prioritized to close the therapeutic divide.
ViiV Healthcare has positioned this approval as a landmark in pediatric care, noting that Tivicay PD is now the first second-generation integrase inhibitor available for this specific age and weight demographic. By securing Priority Review status from the FDA, the company demonstrated the urgency of the medical need, a sentiment echoed by the regulatory body in its approval decision.
Commercial Landscape and GSK’s HIV Portfolio
From a financial perspective, the approval comes at a time when the standalone Tivicay brand is facing a maturation phase. According to fiscal reports from parent company GSK, Tivicay sales have experienced modest stagnation, totaling approximately £1.323 billion in 2025—a slight decline from the £1.350 billion reported in 2024. First-half 2026 data suggests this trend may continue, with sales at £629 million, down 3% on a reported basis.
However, the broader HIV portfolio for GSK remains a robust engine of growth, having generated £7.687 billion in 2025, representing an 11% increase at constant exchange rates. The success of newer, long-acting therapies such as Cabenuva and Apretude, alongside the success of the two-drug regimen Dovato, has effectively diversified the company’s revenue streams. While Tivicay PD is unlikely to move the needle significantly in terms of total volume, its approval reinforces the company’s commitment to the entire lifecycle of HIV care—from the earliest days of life to long-term chronic management.
Implications for Future Pediatric Drug Development
The successful regulatory pathway for Tivicay PD serves as a blueprint for future pediatric drug development. By integrating sophisticated PK modeling with real-world clinical data from global networks like IMPAACT, developers can effectively navigate the regulatory requirements for vulnerable populations. This case also highlights the importance of international clinical trial collaboration, as the inclusion of study sites in South Africa and Thailand was essential to achieving a representative and sufficiently powered dataset.
For public health officials, the approval represents more than just a new label; it represents an infrastructure update. Hospitals and pharmacies must now integrate these dosing guidelines into their neonatal intensive care unit (NICU) protocols. The availability of a dispersible tablet simplifies administration for caregivers, who often face significant hurdles when trying to dose infants with liquid formulations that may require refrigeration or complex measuring tools.
As the medical community continues to strive toward the goal of eliminating pediatric HIV transmission and ensuring that every child born with the virus has access to effective, easy-to-administer therapy, the approval of Tivicay PD stands as a testament to the power of targeted pediatric research. While the number of affected neonates in developed nations remains low, the clinical impact on those individual lives—and the potential for this regimen to be scaled globally—remains a significant advancement in the fight against HIV/AIDS.
